Philogen will be attending the PEGS Europe Virtual Conference from November 9 to 12, 2020.
Co-founder and Chief Scientific Officer, Prof. Dario Neri will give a Keynote Presentation in the Tumor Microenvironment Session (Immunotherapy Stream) on November 10 with the title: Immunocytokines with "Activity on Demand".
Prof. Dario Neri will also give a Lecture in the Antibody-Drug Conjugates Session (Oncology Stream) on November 10 with the title: Antibody-Drug Conjugates (ADCs) and Small-Molecule Drug Conjugates (SMDCs): A Comparative Analysis.
Philogen will be attending the Next Generation Protein Therapeutics & Bioconjugates Summit from November 2 to 5, 2020.
Co-founder and Chief Scientific Officer, Prof. Dario Neri will give a Keynote Lecture with the title: Cancer Therapy Using Antibody-Cytokine Fusion Proteins.
Philogen announces publication of malignant brain tumor study results in Science Translational Medicine.
Press Release
Philogen will be attending the World ADC Digital Conference from September 15 to 18, 2020.
Co-founder and Chief Scientific Officer, Prof. Dario Neri will give a Plenary Lecture on: “Small Molecule-drug Conjugates (SMDCs) & ADCs: A Comparative Evaluation”.
Our co-founder and Chief Scientific Officer, Prof. Dario Neri will join Philogen in a full time capacity. His professional path is featured on the ETH Zurich web site. Read the full story here.
Always ask the important questions
Philogen announces a publication entitled: “A microdosing study with 99mTc-PHC-102 for the SPECT/CT imaging of primary and metastatic lesions in renal cell carcinoma patients”
Link to Paper
Philogen received clinical trial authorisation with NIDLEGYTM in nonmelanoma skin cancer
NIDLEGY authorisation in nonmelanoma skin cancerPR Nidlegy Combination Pack Approval
Philogen received combination pack approval for NidlegyTM
Philogen announces Option Exercise by Janssen
PR Option Exercise by JANSSEN